focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,784.75
Bid: 1,784.00
Ask: 1,785.00
Change: -27.75 (-1.53%)
Spread: 1.00 (0.056%)
Open: 1,792.50
High: 1,802.00
Low: 1,784.50
Prev. Close: 1,812.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 1-Gates, UK take lead in $7.5 bln pledge for children's vaccines

Tue, 27th Jan 2015 16:43

* Vaccine alliance hopes to immunise 300 million children

* Gates donates $1.55 bln, wants to halve child deaths

* GAVI buys vaccines in bulk for poor countries (Adds details, quotes and reactions)

By Stephen Brown

BERLIN, Jan 27 (Reuters) - International donors pledged $7.5billion on Tuesday to immunise 300 million children in poorcountries against deadly diseases such as diarrhoea andpneumonia.

At a Global Alliance for Vaccines and Immunisation (GAVI)conference in Berlin, Microsoft founder Bill Gates and theBritish government topped the donations list at $1.55 billionand $1.5 billion respectively.

German development minister Gerd Mueller said the totalreached $7.54 billion, surpassing GAVI's target of $7.5 billion,despite a stronger dollar complicating funding efforts.

Other major donors included the United States, Norway andGermany. China, a recipient of GAVI assistance early lastdecade, has now become a donor.

"It was a bold ask to world leaders but also a verycompelling case," said GAVI chairman Dagfinn Hoybraten. "In thecourse of five years from 2016 to 2020 we could vaccinateanother 300 million children and avert 5-6 million futuredeaths."

Gates, who has donated $4 billion to GAVI since it began 15years ago, said there had been "amazing" progress but one in 20children still died before their fifth birthday.

"The goal for the next 15 years is to cut that in half againto get it to one in 40," he said.

GAVI has provided vaccines to about 500 million childrenworldwide and saved 6-7 million lives from diseases likepneumonia, hepatitis B, diarrhoea and measles, working with theWorld Health Organisation, UNICEF, World Bank and charities.

Michael Elliott of anti-poverty group One, calling GAVI away for rich countries to give "an infinitesimal part of theirtax money to save lives".

But Save the Children's Jasmine Whitbread said the problemswere still huge: "In some of the world's poorest communitiesonly 16 percent of children are reached by vaccines."

GAVI funds immunisation for countries that cannot affordthem, using its buying power to negotiate discounts from thelikes of GlaxoSmithKline and Pfizer. Medicalcharity Medecins Sans Frontieres argues that it should strikeeven tougher deals.

Pfizer has said it would cut pneumococcal vaccine prices by6 percent for poor countries through 2025, including those thatoutgrow their eligibility for GAVI. GlaxoSmithKline has extendedits price-freeze commitment to 10 years for countries graduatingfrom GAVI and Sanofi will expand production of yellowfever vaccine.

But GAVI's CEO Seth Berkley called the latest discount for pneumococcal vaccine "small" and said he hoped new manufacturerswould emerge to help bring about bigger price reductions. (Editing by Ben Hirschler and Robin Pomeroy)

More News
20 Dec 2023 13:29

GSK buys rights to Hansoh Pharma antibody-drug conjugate

(Sharecast News) - GSK has agreed to buy the rights to an antibody-drug conjugate (ADC) - HS-20093 - from Chinese biopharmaceutical group Hansoh Pharma.

Read more
19 Dec 2023 15:36

German court quashes CureVac patent after challenge by BioNTech

CureVac shares drop 40%Dispute over intellectual property with BioNTech to continue

*

Read more
18 Dec 2023 17:21

Energy stocks lift UK's FTSE 100, Vodafone shines

Vodafone jumps as Iliad offers to merge Italian units

*

Read more
18 Dec 2023 10:07

GSK's dostarlimab trial in endometrial cancer meets primary endpoint

(Alliance News) - GSK PLC on Monday said a trial of dostarlimab in combination with niraparib for treating endometrial cancer has met its primary endpoint.

Read more
18 Dec 2023 07:55

LONDON BRIEFING: Games Workshop seals Amazon deal for Warhammer 40,000

(Alliance News) - Stocks in London were set to retreat slightly on Monday, in line with equity markets in Asia, at the start of the last week before the Christmas holidays.

Read more
18 Dec 2023 07:18

GSK sees success in Jemperli endometrial cancer trial

(Sharecast News) - GSK released positive headline results from the planned analysis of its trial of Jemperli in endometrial cancer on Monday.

Read more
17 Dec 2023 15:16

PRESS: GSK looks for deals in China as rebuilds relationship

(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.

Read more
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:24

GSK seeks to extend RSV vaccine approval in Japan

(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.

Read more
11 Dec 2023 08:28

GSK drug gets EU marketing backing for form of endometrial cancer

(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.